CNBC March 26, 2024
Key Points
– The FDA approved a drug from Merck designed to treat a rare, progressive and life-threatening lung condition called pulmonary arterial hypertension.
– The decision is a big step for the roughly 40,000 people in the U.S. living with that disease because Winrevair is the first drug to target the root cause of the condition.
– The approval is also a win for Merck, which is working to diversify its revenue stream as its blockbuster cancer drug Keytruda approaches a loss of market exclusivity in 2028.
The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for...
Today's Sponsors
Today's Sponsor